SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA's stellar earnings and robust AI-driven guidance were surprisingly met with a sharp sell-off, prompting intense community discussion centered on potential institutional options manipulation and overvaluation fears within the broader AI sector, with many investors actively calling it a strategic dip-buying opportunity.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a reported financial turnaround and an improved outlook, driven by new Material Transfer Agreements, particularly in oncology, and securing a non-dilutive credit facility. The community is actively discussing the company's strategic pivot to its Matrix-M adjuvant platform and the potential for a significant short squeeze.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is highly active ahead of its earnings report and recent management commentary at the CAGNY conference, with community sentiment sharply divided over CEO performance and widespread speculation regarding a potential Pepsi buyout, even as impressive sales growth from Celsius and Alani Nu continues to draw bullish long-term conviction.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is a focal point of market discussion following its strong revenue performance and optimistic long-term guidance, amplified by significant government contract wins and strategic acquisitions, generating intense debate among investors over its valuation, future profitability, and high short interest.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy is trending after a substantial earnings and guidance miss triggered a sharp sell-off, igniting a fierce debate among investors. Many view the dip as an overreaction and a strategic buying opportunity for its energy storage technology, while a vocal segment criticizes management's credibility and forecasts further downside.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending with high anticipation ahead of its earnings report, as its expanding agentic AI platform through new offerings like Sales Assist and a strategic India innovation hub fuels investor excitement, while a notable short interest adds to community speculation about its valuation and growing presence across diverse sectors.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending as a significant earnings beat and robust revenue growth are met with investor frustration over the stock's stagnant price action, igniting community debate and speculation about a potential buyout or partnership amidst management's notable silence regarding its AUR200 pipeline.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending following its mixed Q4 earnings report and the announcement of CEO Doug Ingram's upcoming retirement, fueling community debate around the stock's perceived undervaluation. Investors are actively discussing potential catalysts like upcoming pipeline data from its siRNA programs and renewed buyout speculation, amidst persistent claims of market manipulation.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending following its Q4 2025 earnings report, which surpassed revenue and EPS expectations. This has ignited a community debate, with bulls citing the company's strong free cash flow and deep undervaluation, while bears remain focused on long-term growth challenges and management's execution.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is trending on intense speculation of a potential acquisition by Vertex, further fueled by recent Casgevy revenue reports and ARK Invest's continued buying, with the community actively debating management's performance and anticipating pipeline updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$YMAB NASDAQ Equity Corporate Actions Alert # 2025 - 499 
Information Regarding the Tender Offer of Y-mAbs Therapeutics, Inc. (YMAB)  
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-499 
The tender offer by Yosemite Merger Sub, Inc. a wholly owned subsidiary of Perseus Bidco US, Inc. to acquire all of the outstanding common stock of Y-mAbs Therapeutics, Inc. (YMAB) is scheduled to expire one minute after 11:59 p.m. ET, on September 15, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on September 16, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 15, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (September 16th) and will be suspended effective September 17, 2025. 
 
Tender offer is $8.60 for each share of YMAB.

The tender offer by Yosemite Merger Sub, Inc. a wholly owned subsidiary of Perseus Bidco US, Inc. to acquire all of the outstanding common stock of Y-mAbs Therapeutics, Inc. (YMAB) is scheduled to expire one minute after 11:59 p.m. ET, on September 15, 2025, unless extended or terminated.

Nasdaqtrader

Equity Corporate Actions Alert #2025 - 499 Information Regarding the Tender Offer of Y-mAbs Therapeutics, Inc. (YMAB)

StockTwits Web

Y-Mabs Therapeutics Inc

 NASDAQ Equity Corporate Actions Alert # 2025 - 499 
Information Regarding the Tender Offer of Y-mAbs Therapeutics, Inc. (YMAB)  


 
The tender offer by Yosemite Merger Sub, Inc. a wholly owned subsidiary of Perseus Bidco US, Inc. to acquire all of the outstanding common stock of Y-mAbs Therapeutics, Inc. (YMAB) is scheduled to expire one minute after 11:59 p.m. ET, on September 15, 2025, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on September 16, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on September 15, 2025. If the merger closes as planned, the stock will remain halted on the day of closing (September 16th) and will be suspended effective September 17, 2025. 
 
Tender offer is $8.60 for each share of YMAB.